熱門資訊> 正文
FDA拒绝罕见病药物，Fortress Biotech股价暴跌
2025-10-01 20:59
- Fortress Biotech (NASDAQ:FBIO) fell ~31% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve CUTX-101, a treatment developed by the company and its India-based partner Zydus Lifesciences for a rare condition called Menkes disease.
- In a statement on Wednesday, the Florida-based biotech and its subsidiary Cyprium Therapeutics said that the FDA issued a complete response letter in relation to a New Drug Application for CUTX-101 targeted at pediatric Menkes disease.
- The FDA has cited no approvability concerns in the CRL except manufacturing issues found at a facility where the drug is produced, the company said, adding that the site has already responded to regulatory concerns raised during a September re-inspection of the facility.
- Fortress Biotech (NASDAQ:FBIO) noted that Zydus, which obtained commercial and R&D rights for CUTX-101 in 2023 from Cyprium, will seek a meeting with the FDA to discuss the CRL and a potential resubmission of the NDA.
More on Fortress Biotech
- Seeking Alpha’s Quant Rating on Fortress Biotech
- Historical earnings data for Fortress Biotech
- Financial information for Fortress Biotech
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
